Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial Academic Article uri icon

Overview

MeSH Major

  • Benzamides
  • Lung Diseases, Interstitial
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Scleroderma, Diffuse

abstract

  • This study demonstrates long-term safety and tolerability of imatinib in a substantial proportion of patients with dcSSc. This is important in evaluating the relevance of this therapy in a chronic disease such as SSc.

publication date

  • November 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 25152211

Additional Document Info

start page

  • S

end page

  • 189-93

volume

  • 32

number

  • 6